Total survey error

Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor

Retrieved on: 
Wednesday, January 25, 2023
Rewind, Remyelination, Neurodegeneration, CNS, General partnership, Neuron, Demyelinating disease, Multiple sclerosis, Therapy, Degenerative disease, Total survey error, Central nervous system, Depression, Patient, Anxiety, Irritability, Death, PMV, Doctor of Philosophy, Pharmaceutical industry

Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.

Key Points: 
  • Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics , a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.
  • Claus Andersson, PhD, General Partner at Sunstone Life Science Ventures A/S, will join Rewind Therapeutics´ Board of Directors.
  • "We are delighted to welcome Sunstone Life Science Ventures as a new investor alongside the continued support by our existing investor syndicate," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics.
  • "Moreover, Rewind has a strong patent estate and a team with long research and development expertise in the field of remyelination therapeutics.

Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team

Retrieved on: 
Tuesday, November 29, 2022
GlaxoSmithKline, Doctor of Philosophy, Rewind, GSK, Remyelination, Head, Demyelinating disease, University, Therapy, Bachelor of Science, Patient, Neuroscience, Molecular genetics, Discovery, Optic neuritis, Consultant, PMV, Nerve injury, Biology, Multiple sclerosis, University of Warwick, Roche, Ludwig Cancer Research, Total survey error, Drug discovery, HIV disease progression rates, Medical device, Pharmaceutical industry, Research

Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Dr. Stephen Burbidge has been appointed to the Company´s management team as Head of Research and Discovery.

Key Points: 
  • Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics , a company developing first-in-class treatments for demyelination-associated diseases, today announced that Dr. Stephen Burbidge has been appointed to the Companys management team as Head of Research and Discovery.
  • "We are delighted to welcome Stephen Burbidge at Rewind Therapeutics," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics.
  • "Rewind Therapeutics is focusing on remyelination therapies, an area of increasing importance in treating neurological and nerve-related diseases," said Dr. Stephen Burbidge.
  • Rewinds team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics.

How Gas Sensors Reduce Health Impacts of the Energy Crisis

Retrieved on: 
Thursday, November 3, 2022
Solution, Carbon, Table, Risk, Nitrogen dioxide, Consultant, Subscription business model, Nervous system, Technology, Infarction, Original equipment manufacturer, Death, Smell, OPC, Ventilation, Health, Research, Central heating, Particulates, Adoption, Heat, Total survey error, COVID, Instrumentation

Could gas sensors facilitate the safe use of wood-burning stoves to combat the energy crisis?

Key Points: 
  • Could gas sensors facilitate the safe use of wood-burning stoves to combat the energy crisis?
  • By continuously monitoring air quality, gas sensors enable wood-burning stoves to be used while minimizing the risk of toxic indoor air pollution.
  • Domestic gas sensors have long played a role within carbon monoxide alarms and even smoke detectors.
  • Technology of interest includes infra-red sensors, metal oxide semiconductors, electrochemical sensors, photo-acoustic sensors, and even carbon nanotubes.

How Gas Sensors Reduce Health Impacts of the Energy Crisis

Retrieved on: 
Thursday, November 3, 2022
Solution, Carbon, Table, Risk, Nitrogen dioxide, Consultant, Subscription business model, Nervous system, Technology, Infarction, Original equipment manufacturer, Death, Smell, OPC, Ventilation, Health, Research, Central heating, Particulates, Adoption, Heat, Total survey error, COVID, Instrumentation

Could gas sensors facilitate the safe use of wood-burning stoves to combat the energy crisis?

Key Points: 
  • Could gas sensors facilitate the safe use of wood-burning stoves to combat the energy crisis?
  • By continuously monitoring air quality, gas sensors enable wood-burning stoves to be used while minimizing the risk of toxic indoor air pollution.
  • Domestic gas sensors have long played a role within carbon monoxide alarms and even smoke detectors.
  • Technology of interest includes infra-red sensors, metal oxide semiconductors, electrochemical sensors, photo-acoustic sensors, and even carbon nanotubes.

Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer

Retrieved on: 
Wednesday, October 19, 2022
Rewind, Nerve injury, Disease, Therapy, CSO, PD, Swiss Federal Institute of Aquatic Science and Technology, Science, Multiple sclerosis, Optic neuritis, Patient, Total survey error, Research, HIV disease progression rates, University, Company, Drug discovery, Doctor of Philosophy, Industry, Remyelination, CNS, Demyelinating disease, Head, University of Zurich, California Institute for Quantitative Biosciences, Swiss Federal Institute of Technology, Molecular neuroscience, Neurodegeneration, PMV, Pharmaceutical industry

Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Company´s Chief Scientific Officer.

Key Points: 
  • Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics , a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Companys Chief Scientific Officer.
  • "We warmly welcome Irene as our new CSO and are excited that she joins Rewind," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics.
  • Our goal is to progress to a clinical-stage portfolio company and we know Irene will play a significant role in advancing Rewind."
  • "Rewind Therapeutics has built a great team and comprehensive expertise in remyelination," said Irene Knuesel, Chief Scientific Officer at Rewind Therapeutics.

Austal USA awarded $3.3 billion multi-ship contract for U.S. Coast Guard Offshore Patrol Cutter (OPC)

Retrieved on: 
Friday, July 1, 2022
Acquisition, Ageing, U.S. Coast Guard environmental protection, Aluminium, Austal, GLOBE, Coast guard, Total survey error, Law enforcement, Coast, Commerce, United States Coast Guard Yard, VA-52 (U.S. Navy), AFDM, USCG, Arctic, OPC, Program, Austal USA, Mining, Shipbuilding

Mobile, Ala., June 30, 2022 (GLOBE NEWSWIRE) -- Austal USA was awarded a contract with a potential value of $3.3 billion for the detail design and construction of up to 11 Offshore Patrol Cutters (OPC) for the United States Coast Guard (USCG).

Key Points: 
  • Mobile, Ala., June 30, 2022 (GLOBE NEWSWIRE) -- Austal USA was awarded a contract with a potential value of $3.3 billion for the detail design and construction of up to 11 Offshore Patrol Cutters (OPC) for the United States Coast Guard (USCG).
  • The Austal USA team is excited to support the U.S. Coast Guard using our new steel panel line to manufacture and deliver ships highly capable of performing their critical homeland security and defense missions, Austal USA President Rusty Murdaugh said.
  • Through continual capital investments, Austal USA has expanded its capability and capacity to enable concurrent production of aluminum and steel-hulled ships.
  • This unique production capability positions Austal USA to meet the growing demands of the U.S. Navy and USCG.

Ian Thorpe unveiled as Anthogenol Brand Ambassador

Retrieved on: 
Monday, June 13, 2022
Life, Oligomer, Grape, Antioxidant, Vegetarianism, Veganism, Pharmacy, Research, Coles, Lists of Olympic medalists, Silicon, Time-invariant system, READ, Chemistry (relationship), Grape seed extract, Chemist Warehouse, Health, RRP, Seed, Total survey error, Originality, Capsule, Dietary supplement, Priceline, Masquelier

June 3rd, 2022: Partnering with Australian swimming legend Ian Thorpe, Anthogenol(R) looks to continue to set the bar globally for antioxidant supplements that offer real, tangible results.

Key Points: 
  • June 3rd, 2022: Partnering with Australian swimming legend Ian Thorpe, Anthogenol(R) looks to continue to set the bar globally for antioxidant supplements that offer real, tangible results.
  • The Olympian perfectly represents the brand's prominence, authority and credibility in the health and wellness space.
  • In 1948, Professor Jack Masquelier helmed a scientific breakthrough when he successfully isolated the powerful antioxidants Oligomeric proanthocyanidins (OPCs).
  • It is exciting to work with a brand that allows Australians to get more out of life."

Ian Thorpe unveiled as Anthogenol Brand Ambassador

Retrieved on: 
Monday, June 13, 2022
Life, Oligomer, Grape, Antioxidant, Vegetarianism, Veganism, Pharmacy, Research, Coles, Lists of Olympic medalists, Silicon, Time-invariant system, READ, Chemistry (relationship), Grape seed extract, Chemist Warehouse, Health, RRP, Seed, Total survey error, Originality, Capsule, Dietary supplement, Priceline, Masquelier

June 3rd, 2022: Partnering with Australian swimming legend Ian Thorpe, Anthogenol(R) looks to continue to set the bar globally for antioxidant supplements that offer real, tangible results.

Key Points: 
  • June 3rd, 2022: Partnering with Australian swimming legend Ian Thorpe, Anthogenol(R) looks to continue to set the bar globally for antioxidant supplements that offer real, tangible results.
  • The Olympian perfectly represents the brand's prominence, authority and credibility in the health and wellness space.
  • In 1948, Professor Jack Masquelier helmed a scientific breakthrough when he successfully isolated the powerful antioxidants Oligomeric proanthocyanidins (OPCs).
  • It is exciting to work with a brand that allows Australians to get more out of life."

THERADERM OPC REPARATIVE SERUM WINS 2022 NEWBEAUTY AWARD

Retrieved on: 
Tuesday, April 5, 2022
Cream, Serum, Cell, OPC, Antioxidant, Skin, Vitamin E, Rosacea, Chemistry (relationship), Sun, CEO, Vitamin C, Award, Quality of life, Hyaluronic acid, Elastin, Red, Inflammation, Ageing, Plastic surgery, Smoke, Solution, Theraderm, OXO-biodegradation, UV, Patient, Total survey error, Cosmetics

SPRINGDALE, Ariz., April 5, 2022 /PRNewswire/ -- Therapon Skin Health, the makers of the medical-grade skin care line Theraderm® Clinical Skin Care, is proud to announce that its OPC Reparative Serum has earned a 2022 Beauty Award. The serum, which harnesses an antioxidant concentration that is proven to be 20x more effective than Vitamin C as a free radical scavenger, was named 'The Best After Sun Treatment' by NewBeauty's panel of experts.

Key Points: 
  • SPRINGDALE, Ariz., April 5, 2022 /PRNewswire/ -- Therapon Skin Health, the makers of the medical-grade skin care line Theraderm Clinical Skin Care , is proud to announce that its OPC Reparative Serum has earned a 2022 Beauty Award.
  • The Awards, announced in the NewBeauty Spring 2022 issue, showcase the top treatments and products across various categories.
  • Winners are chosen through rigorous testing by industry experts, NewBeauty editors and readers.
  • Theraderm's OPC Reparative Serum helps reverse sun damage, redness and inflammation with supercharged antioxidants called OPCs (oligomeric proanthocyanidins), which reduce redness and inflammation while protecting skin from free radical damage and visibly reducing signs of aging.

Pipeline Therapeutics Reports Positive Phase 1 Clinical Results for PIPE-307, a Neuroregenerative Therapeutic for the Treatment of Multiple Sclerosis

Retrieved on: 
Thursday, March 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Safety, Attention, Multiple sclerosis, Volunteering, Single, Senior, MAD, Company, IND, MS, Pharmacokinetics, Even and odd functions, Total survey error, Food, CNS, Neurodegeneration, Investigational New Drug, Inflammatory demyelinating diseases of the central nervous system, Learning, Patient, SAD, US Foods, Nerve, Therapy, PK, Program, CEO, Veps, Adult, Neuro, LinkedIn, Pharmaceutical industry, Pipeline, PIPE-307 for Multiple Sclerosis, Pipeline Therapeutics, PIPE-307 FOR MULTIPLE SCLEROSIS, PIPELINE THERAPEUTICS

Currently, there are no approved medicines that support myelin restoration, which represents a significant unmet medical need in the treatment of MS.

Key Points: 
  • Currently, there are no approved medicines that support myelin restoration, which represents a significant unmet medical need in the treatment of MS.
  • The Phase 1 clinical results reported today comprised multiple dose cohorts of PIPE-307 in a total of 70 healthy volunteer subjects.
  • We believe that PIPE-307, as a first-in-class myelin restoration therapeutic, represents a differentiated and clinically-validated approach for the treatment of MS.
  • These encouraging Phase 1 results give us great confidence to advance PIPE-307 into clinical studies with MS patients as soon as possible.